Abstract

Background and objectives Allium elburzense is an endemic plant in north of Iran with some nutritional and medicinal applications; however, there is no data on its safety profile. This study was aimed to investigate cytotoxicity, acute and sub-acute toxicity of hydroalcoholic extract of A. elburzense bulb. Methods Total phenolic content of the extract was measured using Folin-Ciocalteumethod. For cytotoxicity assay, human umbilical vein endothelial cells (HUVECs) were used. In acute toxicity study, single oral dose of 2000 mg/kg was administered in female and male Wistar rats and they were monitored for two weeks. In sub-acute test, 125, 250 and 500 mg/kg/day of extract were orally administered for four weeks. Results Total phenolic content was estimated as 32.8 ± 2.5 mg gallic acid equivalent/g of the extract. The extract showed IC50 value of 366.4 µg/mL (95% CI = 246.4-566.1) in HUVECs after 24 h exposure. In acute study, there was no sign of toxicity and no mortality; however, significant increase in relative spleen weight and ALP activity and mild inflammation in kidney tissue were observed. LD50 ˃ 2000 mg/kg was estimated for A. elburzense bulb extract. In sub-acute assay, there were significant elevations in relative spleen weight, blood urea level, AST, ALT, ALP, total WBC, lymphocyte and neutrophil count and significant decrease in blood sugar and triglyceride levels at higher doses of the extract. ConclusionAllium elburzense bulb extract may be considered as safe at doses lower than 500 mg/kg in rats; however, assessment of liver and kidney functions is recommended during chronic uses.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.